Navigation Links
Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
Date:9/18/2012

CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today the appointment of two new independent Directors to the Company's Board of Directors. Scott A. Canute and Gino Santini provide Inspiration access to unparalleled expertise in biopharmaceuticals manufacturing and business development as the company moves toward commercialization of its portfolio of products currently in late-stage development for hemophilia. The new independent Directors were appointed by specialty pharmaceutical company Ipsen, who holds rights to commercialize Inspiration's two late-stage hemophilia product candidates in Europe and certain other territories. Ipsen gained the right to designate two new members to Inspiration's board under the terms of agreements announced by the companies on August 21, 2012.

"We are pleased to have our Board enhanced by these talented executives," said John Taylor, Co-Founder and Chairman of the Board of Inspiration. "They deeply understand Inspiration's mission to broaden treatment choices, expand global access to care and advance innovative therapies for the hemophilia community. Each brings a unique set of experiences that will be instrumental to Inspiration as we continue to develop as an independent company and work to create new products to help people with hemophilia."

Scott A. Canute has over 30 years of experience in the biopharmaceutical industry. He has most recently served as the President of Global Manufacturing and Corporate Operations and Executive Vice President of Genzyme Corporation from March 2010 to July 2011, leading a major turnaround effort for the manufacturing division of the global biotechnology company. Prior to that, Mr. Canute spent 25 years at Eli Lilly and Company in a variety of positions culminating in his becoming President of Manufacturing in 2004. Mr. Canute is currently a board member of Oncobiologics, Inc. and has been a past board member of the Indiana Manufacturers Association and the National Association of Manufacturers. Mr. Canute holds a Bachelor of Science Degree in Chemical Engineering from the University of Michigan and a Master of Business Administration from the Harvard Business School.

Gino Santini is a senior advisor for venture capital, pharmaceutical and biotechnology companies. He is currently a board member of AMAG Pharmaceuticals, Horizon Pharma, SORIN SpA, Allena Pharmaceuticals and Collegium Pharmaceuticals. He retired from Eli Lilly and Company in 2011 as Senior Vice President of Corporate Strategy and Business Development after 27 years with the company, where he had been a member of the Executive Committee since 2004. From 1999 to 2004, he was President of U.S. Operations. Mr. Santini is a past Chairman of the Board of the National Pharmaceutical Council. He also served on the Board of Directors of the United Way and the Executive Committee and Board of the Indianapolis Chamber of Commerce. Mr. Santini holds a degree in mechanical engineering from the University of Bologna and a Master of Business Administration from the Simon School of Business, University of Rochester.

"These new appointments to our Board of Directors bring critical expertise to Inspiration," said John P. Butler, Chief Executive Officer. "Scott and Gino have vast experience in areas that are vital to us as a growing biopharmaceutical company on the verge of commercialization. Scott's manufacturing expertise is unparalleled in the industry. Gino has decades of experience in the development and negotiation of strategic partnerships and alliances, which will help Inspiration choose the best path as we move forward. With these additions, Inspiration's Board of Directors is ideally suited to help us develop innovative treatment options that meet the needs of the global hemophilia community."

More information about Inspiration's Board of Directors is available on the Board of Directors page at www.inspirationbio.com.

About Inspiration BiopharmaceuticalsAs the only biopharmaceutical company dedicated solely to hemophilia, Inspiration is committed to improving the care of people with this condition by broadening treatment choices, expanding global access to care and advancing innovative therapies. Founded by two families whose sons have hemophilia, Inspiration is inspired to make a difference in the lives of people impacted by hemophilia around the world. Inspiration's lead product candidates are IB1001, an investigational intravenous recombinant factor IX being developed for the treatment of hemophilia B, and OBI-1, an investigational recombinant porcine factor VIII being developed for the treatment of serious bleeds in patients with congenital hemophilia A with inhibitors or acquired hemophilia A.

For more information about Inspiration Biopharmaceuticals, please visit www.inspirationbio.com.Contacts:Media  InvestorsKate LewisGordon H. BusenbarkFeinstein Kean HealthcareSenior Vice President, Chief Financial OfficerTel: +1-617-577-8Tel: +1-617-588-1802Email: kate.lewis@fkhealth.com  


'/>"/>
SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
7. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
8. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
10. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
11. The Thousand-Year Business Model for a Modern Biopharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):